Guggenheim Rates Travere Therapeutics (TVTX) buy

Guggenheim maintains its buy rating on Travere Therapeutics with a $65 price target, a 10.45% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 11:01 AM EDT · Updated Jun 29, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Travere Therapeutics, Inc. ($TVTX) "buy" with a $65 price target on June 25, 2026.

Since the rating, $TVTX is down 3.6% after 1 week, down 4.0% after 1 month and down 16.0% to date (from the $59.03 close on Jun 25, 2026).

TVTX Travere Therapeutics, Inc.

$49.60 +25.51% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim analyst Vamil Divan reiterated a buy rating on Travere Therapeutics, Inc. (TVTX) with a $65 price target on June 25, 2026.
Guggenheim's $65 price target implies 10.45% upside from Travere Therapeutics, Inc.'s ($TVTX) current $58.85 share price.
Shares of Travere Therapeutics traded near $57.69 on Thursday, with a market cap of approximately $5.12 billion and a forward P/E of 11.36.
Several insiders sold shares in June 2026, and analysts from multiple firms maintain a buy rating with targets as high as $70.

Get $TVTX trade alerts by text

We text you when insiders, Congress or big funds trade $TVTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Travere Therapeutics, Inc. alert may contain errors. Disclosures

Guggenheim analyst Vamil Divan reaffirmed a buy rating for Travere Therapeutics, Inc. (NasdaqGM: TVTX) on June 25, 2026. The firm set a price target of $65, indicating confidence in the company's future performance. Shares of Travere traded near $57.69 on Thursday.

Travere Therapeutics, Inc. Stock Down 6.2%

Shares of Travere Therapeutics, Inc. traded near $57.69 on Thursday. The company has a market capitalization of about $5.12 billion and a forward P/E ratio of 11.36. With a beta of 1.141, the stock has shown some volatility. Its 52-week range spans from a low of $13.97 to a high of $56.81. The stock's 50-day moving average is approximately $43.80, and its 200-day moving average is around $33.62. Travere's current ratio is 3.131, and its quick ratio is 2.816, while its debt-to-equity ratio stands at 331.884.

12-month forecast

$TVTX price target

Travere Therapeutics, Inc. daily closes and this analyst's $65 target. Not advice.

Insider Buying and Selling at Travere Therapeutics, Inc.

In June 2026, several insiders at Travere Therapeutics engaged in stock transactions. Chief Medical Officer Jula Inrig sold 468 shares on June 22. On June 12, Roy Baynes sold 4,500 shares at an average price of $50.00 under a planned sale, while also buying 4,500 shares at $21.38. Timothy Coughlin sold 10,000 shares and also bought 10,000 shares on the same day at $26.52.

Analysts Set New Price Targets

On June 25, 2026, Guggenheim reiterated its buy rating for Travere Therapeutics with a $65 price target. Other analysts have also shown optimism, with Wedbush maintaining a buy rating and a $61 target on June 22, and Evercore ISI Group holding a buy rating with a $60 target on June 18. Citigroup, on June 15, set a target of $70 while maintaining its buy rating. Overall, the consensus recommendation is a strong buy, with an average target price of $57.29 from 14 analysts.

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing and delivering therapies for rare kidney and metabolic diseases. The company's products include FILSPARI and Thiola, which target conditions like IgA Nephropathy and cystinuria, respectively. Travere is also working on clinical-stage programs such as Sparsentan and Pegtibatinase. Led by CEO Dr. Eric M. Dube, the company employs 497 people.

Bottom Line

Guggenheim's reiterated buy rating and $65 price target reflect confidence in Travere Therapeutics' potential. Investors track such ratings closely, as they can influence market sentiment. It's important to remember that analyst ratings are based on past data and projections, and actual performance may vary.